Intellia Therapeutics' (NTLA) Buy Rating Reaffirmed at Chardan Capital

Chardan Capital reaffirmed their buy rating on shares of Intellia Therapeutics (NASDAQ:NTLA - Free Report) in a report released on Friday,Benzinga reports. They currently have a $68.00 price objective on the stock.

A number of other brokerages have also recently commented on NTLA. StockNews.com raised shares of Intellia Therapeutics to a "sell" rating in a research report on Monday, March 3rd. Morgan Stanley downgraded Intellia Therapeutics from an "overweight" rating to an "equal weight" rating and lowered their target price for the stock from $56.00 to $11.00 in a report on Monday, January 27th. Wedbush restated a "neutral" rating and set a $10.00 price target (down from $14.00) on shares of Intellia Therapeutics in a report on Friday, January 10th. BMO Capital Markets lowered their target price on shares of Intellia Therapeutics from $70.00 to $50.00 and set an "outperform" rating for the company in a report on Friday, January 10th. Finally, Wolfe Research upgraded shares of Intellia Therapeutics from a "peer perform" rating to an "outperform" rating and set a $21.00 price target on the stock in a report on Monday, April 21st. Two analysts have rated the stock with a sell rating, six have assigned a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $36.90.

Intellia Therapeutics Stock Down 2.7%

Intellia Therapeutics stock traded down $0.23 during trading hours on Friday, hitting $8.32. The stock had a trading volume of 3,424,764 shares, compared to its average volume of 2,485,444. The business's 50 day simple moving average is $8.11 and its 200-day simple moving average is $10.91. Intellia Therapeutics has a one year low of $5.90 and a one year high of $28.18. The stock has a market cap of $861.81 million, a price-to-earnings ratio of -1.53 and a beta of 2.33.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported ($1.10) EPS for the quarter, topping the consensus estimate of ($1.26) by $0.16. The business had revenue of $16.63 million for the quarter, compared to analyst estimates of $11.39 million. During the same quarter in the prior year, the business earned ($1.12) earnings per share. The firm's quarterly revenue was down 42.6% on a year-over-year basis. Research analysts anticipate that Intellia Therapeutics will post -5.07 EPS for the current fiscal year.

Institutional Trading of Intellia Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. American Century Companies Inc. increased its position in shares of Intellia Therapeutics by 3.9% during the first quarter. American Century Companies Inc. now owns 471,676 shares of the company's stock valued at $3,354,000 after buying an additional 17,855 shares during the period. Fox Run Management L.L.C. bought a new stake in Intellia Therapeutics during the 1st quarter worth approximately $132,000. HighTower Advisors LLC increased its holdings in Intellia Therapeutics by 8.2% during the 1st quarter. HighTower Advisors LLC now owns 16,921 shares of the company's stock worth $120,000 after acquiring an additional 1,282 shares during the period. Nuveen LLC purchased a new stake in Intellia Therapeutics in the 1st quarter worth approximately $1,936,000. Finally, Entropy Technologies LP boosted its holdings in Intellia Therapeutics by 108.3% in the 1st quarter. Entropy Technologies LP now owns 31,315 shares of the company's stock valued at $223,000 after purchasing an additional 16,284 shares during the period. 88.77% of the stock is currently owned by institutional investors.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.